Why the study?
Severe aortic stenosis carries high mortality if untreated and many high-risk patients cannot undergo surgical AVR, making TAVI a less invasive alternative whose local outcomes needed evaluation.
What are the procedural and mid-term outcomes of TAVI using balloon-expandable valves in high-risk patients with severe symptomatic aortic stenosis?
What are the procedural and mid-term outcomes of TAVI using balloon-expandable valves in high-risk patients with severe symptomatic aortic stenosis?
Answers are grounded in this paper and cite their sources.
TAVI using balloon-expandable valves under conscious sedation is a safe and effective treatment for high-risk patients with severe aortic stenosis, demonstrating high procedural success and acceptable mid-term mortality.
Background: Aortic stenosis (AS) is a progressive disease with high mortality if untreated; however, many high-risk patients do not receive surgical aortic valve replacement (AVR) due to comorbidities. Transcatheter aortic valve implantation (TAVI) offers a less invasive therapeutic choice. Objectives: This study evaluated the outcomes of TAVI at the Shahid Modarres Educational and Therapeutic Center in Iran. Methods: In this cross-sectional study, 100 consecutive patients (77.82 ± 6.97 years) with severe symptomatic AS underwent TAVI using balloon-expandable valves under conscious sedation over 3 years. Pre-procedural assessments included echocardiography and computed tomography (CT) angiography. The procedure was performed via transfemoral access under fluoroscopic guidance. Outcomes assessed included procedural complications, mortality at 30 days and 6 months, and echocardiographic data pre- and post-procedure. Results: The TAVI was successful in 99% of patients. Procedural complications occurred in 12%, with a mortality rate of 1%. Post-procedure, the mean pressure gradient (MPG) was 9.75 ± 6.19 mmHg and the peak pressure gradient (PPG) was 19.25 ± 10.15 mmHg. Mortality at 30 days was 3%, increasing to 6% by 6 months, while 23% were hospitalized for any cause within 6 months. Notable correlations were found between gradient improvement (ΔMPG and ΔPPG) and factors such as aortic valve area (AVA) and left ventricular ejection fraction (LVEF). Conclusions: Initial experiences with TAVI at our center indicate it is a safe and effective treatment for high-risk patients with severe AS, with positive mid-term outcomes underscoring the need for careful patient selection and management.
No takes yet. Share an insight, caveat, or question.
Namazi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: